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Abstract: Gliomas have been classified according to their histological properties. However, their respective cells of 
origin are still unknown. Neural progenitor cells (NPC) from the subventricular zone (SVZ) can initiate tumors in mu-
rine models of glioma and are likely cells of origin in the human disease. In both, p53 signaling is often functionally 
impaired which may contribute to tumor formation. Also, TGF-beta, which under physiological conditions exerts a 
strong control on the proliferation of NPCs in the SVZ, is a potent mitogen on glioma cells. Here, we approach on the 
crosstalk between p53 and TGF-beta by loss of function experiments using NPCs derived from p53 mutant mice, as 
well as pharmacological inhibition of TGF-beta signaling using TGF-beta receptor inhibitors. NPC derived from p53 
mutant mice showed increased clonogenicity and more rapid proliferation than their wildtype counterparts. Further, 
NPC derived from p53mut/mut mice were insensitive to TGF-beta induced growth arrest. Still, the canonical TGF-beta 
signaling pathway remained functional in the absence of p53 signaling and expression of key proteins as well as 
phosphorylation and nuclear translocation of SMAD2 were unaltered. TGF-beta-induced p21 expression could, in 
contrast, only be detected in p53wt/wt but not in p53mut/mut NPC. Conversely, inhibition of TGF-beta signaling using 
SB431542 increased proliferation of p53wt/wt but not of p53mut/mut NPC. In conclusion, our data suggest that the TGF-
beta induced growth arrest in NPC depends on functional p53. Mutational inactivation of p53 hence contributes to 
increased proliferation of NPC and likely to the formation of hyperplasia of the SVZ observed in p53 deficient mice 
in vivo.
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Introduction
Glioblastoma multiforme (GBM) is both the 
most common and the most lethal human brain 
tumor. In spite of histological similarities betw- 
een GBM cells and astrocytes, the cell of origin 
and the events causing malignant transforma-
tion are still matter of debate [1]. Several lines 
of evidence mainly based on data from animal 
models indicate that cells of the neurogenic 
areas in the adult murine brain [2-5], i.e. the 
subventricular zone and the hippocampus can 
give rise to GBM even though other publica-
tions also report the transformation of mature 
brain cells including neurons [6]. In human 
GBM, p53 signaling is mostly dysfunctional, 
either directly due to mutations (in ~28% of pri-
mary and 65% of secondary GBM) [7, 8] or indi-
rect due to dysfunctional regulatory proteins 
like MDM2 [9]. According to the TCGA (Total 
Cancer Genome Atlas) project which analyzed 
mainly primary GBM, the overall frequency of 
genetic alterations in the TP53/MDM2/MDM4/
p14ARF pathway was 87%, with TP53 mutations 
or homozygous deletion being observed in 35%, 
MDM2 amplification in 14%, MDM4 amplifica-
tion in 7% and p14ARF homozygous deletion or 
mutation in 49% of the sequenced GBM [10]. In 
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line with the crucial role for p53 in the genesis 
of GBM, most murine models of spontaneous 
GBM require mutant/dysfunctional p53. In a 
mouse model using conditionally inactivated 
p53 in the brain, tumors developed from neural 
progenitor cells (NPC) in the subventricular 
zone (SVZ) [4, 5, 11-13]. This is corroborated by 
a study reporting increased proliferation and 
hyperplasia in the SVZ of mice with mutated 
p53 [14]. To enhance tumor formation, murine 
GBM models use a “second hit” like PTEN inac-
tivation or indirect activation of ras signaling via 
NF-1 inactivation [5, 12], which maximally 
increases the proliferation of malignant and 
premalignant cells in the hyperplastic SVZ and 
elsewhere [11]. In human, p53 mutations pre-
dispose for GBM formation in patients with 
Li-Fraumeni Fanconi syndrome [15]. However, 
the reasons why p53 mutations result in 
increased proliferation of cells within the SVZ 
have not been elucidated in detail.
TGF-beta 1 is a very potent inhibitor of NPC pro-
liferation in vitro and abundantly expressed in 
the brain in vivo. Treatment of murine NPC cul-
tures with TGF-beta 1 results in a long-term pro-
liferation arrest that does not affect major stem 
cell properties [16, 17]. Furthermore, it regu-
lates neurogenesis in vivo and contributes to 
the age-associated reduction of NPC prolifera-
tion in the SVZ [18, 19]. In GBM, TGF-beta 1/2 
exerts a variety of pro-tumorigenic functions 
and is likely the most potent contributor to local 
immunosuppression in at least a subgroup of 
GBM [20, 21].
TGF-beta belongs to a cytokine superfamily and 
exerts its effects by canonical signaling via 
SMAD proteins. Still, non-canonical signaling 
e.g. via ras and PI-3 kinase can also be initiated 
by the TGF-beta receptor complex. In the case 
of TGF-beta 1/2, binding to its receptor results 
in phosphorylation of SMAD2, which dimerizes 
with SMAD4 and translocates into the nucleus 
[22, 23]. For DNA binding, the SMAD2/4 com-
plex requires transcriptional cofactors which 
determine the manifold and highly cell type-
specific biological effects of canonical TGF-
beta signaling. P53 is one of these cofactors 
involved in TGF-beta induced cell cycle arrest, 
in transcription of certain target genes, and 
in translocation of the SMAD2/4 com- 
plex into the nucleus [24]. A mutant-p53/Smad 
complex was described to differentially regu-
late 5 genes (Sharp-1/DEC2/BHLHB3, Cyclin 
G2/CCNG2, ADAMTS9, Follistatin, and GPR87), 
to oppose the transcription of p63-dependent 
genes and thereby to empower TGF-beta-
induced metastasis [25]. Still, the role of p53 
in regulating and mediating TGF-beta induced 
proliferation arrest in NPC is unknown. We now 
hypothesized that lack of functional active p53 
may impair TGF-beta-induced growth arrest 
and thereby provide an explanation for the 




B6.129S2-Trp53tm1Tyj/J heterozygous breeding 
pairs were obtained from Charles River. For 
genotyping, DNA was isolated from clipped tails 
and PCR was performed using the primers 
5’-ACAGCGTGGTGGTACCTTAT-3’, 5’-TATACTCAG- 
AGCCGGCCT-3’ (oIMR037), 5’-CTATCAGGACAT 
AGCGTTGG-3’, yielding a fragment of 400 bp 
for p53+/+ and 600 bp for p53-/- mice. 2 differ-
ent clones per condition were investigated; 
mice were littermates from heterozygeouswt/mut 
breeding couples.
Neural progenitor cell culture
Mice (Charles River Deutschland GmbH, Ger- 
many) were decapitated and SVZs were dis-
sected as previously described [26]. The tissue 
was homogenized and cells were resuspend- 
ed in Neurobasal (NB) medium (Gibco BRL, 
Germany) containing B27 supplement (Gibco 
BRL, Germany), 2 mM L-glutamine (PAN, Ger- 
many), 100 U/ml penicillin/100 μg/ml strepto-
mycin (PAN, Germany). For expansion, the NB/
B27 medium was supplemented with 2 ng/ml 
heparin (Sigma, Germany), 20 ng/ml FGF-2 
(R&D Systems, Germany), and 20 ng/ml EGF 
(R&D Systems, Germany), yielding an efficient 
proliferation medium. For all experiments, NPC 
were treated with recombinant human TGF-
beta 1 and recombinant human TGF-beta 2 
(both from Peprotech) using 10 ng/ml of each 
unless indicated otherwise.
Reverse transcriptase PCR
Total RNA was extracted from cells using the 
RNeasy Mini Kit (Qiagen, Germany) according 
to the manufacturer’s instructions. 1 µg of total 
RNA was used to synthesize single stranded 
cDNAs using reverse transcription kit (Pro- 
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mega, USA). PCRs were performed for 30 cycles 
(30 seconds at 94°C, 2 minutes at 66°C and 1 





SDS-PAGE and western blot analysis
Total cell lysates were prepared in the presence 
of phosphatase inhibitor cocktail 1 (Sigma) 
according to the manufacturer’s instructions. 
For Western Blot analysis of TFGR2, p21, and 
phosphorylated Smad2 protein, 20-30 μg of 
total cell lysates were separated by 10-15% 
SDS-PAGE and transferred onto nitrocellu- 
lose membranes. The membranes were pro- 
bed overnight at 4°C with antibodies against 
TGFBR2 (1:1000 Upstate), p21 (1:1000 Santa 
Cruz Biotechnology), pSmad2 (1:1000 Calbio- 
chem), SMAD2 (1:1000, BioNordica), and beta-
actin (1:5000, Abcam, Cambridge, UK).
Alamar blue assay
This assay measures metabolic activity, which 
is a measure for cell proliferation. It is based 
on oxidation-reduction reaction (REDOX) and 
incorporates a fluorometric/colorimetric RED- 
OX indicator that fluoresces and changes color. 
The non-toxic REDOX indicator is cell-permeant 
and serves as electron acceptor in the respira-
tory chain. The ensuing reduction causes the 
REDOX indicator to change from oxidized (non-
fluorescent, blue) form to reduced (fluorescent, 
red) form. The ratio of both forms was photo-
metrically quantified.
Clonogenicity assay
Cells were seeded as indicated in 96 well plates 
and treated as indicated. 10 wells with 50 cells 
were plated for each condition. Depending on 
the growth rate of various cell lines, the medi-
um supplemented with TGF-beta was replaced 
weekly. At the end of 1-2 weeks the number of 
spheres/patches formed was determined.
Immunocytochemistry
Cells were plated in 24 well plates in neurobas-
al medium. After 5 days, cells were fixed using 
4% PFA. Fixed cells were washed in TBS (0.15 
M NaCl, 0.1 M Tris-HCl, pH 7.5), blocked with 
TBS supplemented with 0.1% Triton-X100 (only 
for intracellular antigens), 1% bovine serum 
albumin (BSA), and 0.2% teleostean gelatin 
(Sigma, Taufkirchen, Germany). This solution 
was also used during the incubations with 
antibodies. Smad2 primary antibody (1:1000 
Santa Cruz, USA) was applied overnight at 4°C. 
Stainings were visualized using anti-rabbit 
Alexa Fluor 488 (1:100, Molecular Probes, Lei- 
den and NL) conjugates. Nuclei were counter-
stained using DAPI (1:10000, Sigma-Aldrich). 
Specimens were mounted on microscope 
slides using Prolong Antifade kit (Molecular 
Probes, U.S.A.). Epifluorescence observation 
and photo-documentation were realized using 
a Leica microscope (Leica Mikroskopie und 
Systeme GmbH, Germany) equipped with a 
Spot™ digital camera (Diagnostic Instrument 
Inc, U.S.A.).
Statistics
Data analysis was performed using Graphpad 
Prism 5. The statistical tests used are indicat-
ed in the figure legends. All data are given as 
Mean and Standard Error of the Mean (SEM). 
The statistical significance was assessed using 
a two-sided student’s t-test. A p-value <0.05 
was considered significant.
Results
P53mut/mut NPC show enhanced proliferation 
compared to p53wt/wt
TGF-beta 1 which is abundantly expressed in 
the brain is a potent inhibitor of proliferation of 
NPC in vitro and in vivo [16, 27]. Given that 
crosstalk between TGF-beta and p53 signal- 
ing has been described, we wondered whether 
the increased in vitro and in vivo proliferation 
rate of p53mut/mut NPC could be connected to 
differential responses towards TGF-beta. We 
therefore compared the effects of TGF-beta 
1/2 on murine NPC cells derived from the SVZ 
of 10-14 week old wildtype and p53mut/mut mice. 
Plating of single cells from p53wt/wt and p53mut/
mut NPC cultures revealed that mutant cells give 
rise to much larger neurospheres (Figure 1A, 
1B) and display higher clonogenicity (Figure 
1C). In line with previous reports, p53mut/mut 
NPC also showed increased proliferation as 
measured via the amplification rate (i.e. the 
number of cells after 5 days compared to the 
number of cells plated, Figure 1D) [14].
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TGF-beta-induced growth inhibition of NPC de-
pends on functional p53
In line with a report by Wachs et al. [16, 27], 
addition of TGF-beta 1/2 substantially impaired 
growth and proliferation of NPC cultures from 
wildtype mice (Figure 2A, 2B). In contrast, pro-
liferation of p53mut/mut NPC did not change in 
response to TGF-beta 1/2 (Figure 2A, 2B). This 
effect was specific since inhibition of TGF-beta 
signaling by the specific TGF-beta receptor 
kinase inhibitor SB431542 prevented TGF-beta 
induced growth inhibition in p53wt/wt NPC 
whereas p53mut/mut NPC were not only insensi-
tive to TGF-beta itself, but also to the inhibitor 
(Figure 2C, 2D). Consequently, autocrine TGF-
beta signaling (which would also be affected by 
SB431542) does not seem to be relevant for 
p53mut/mut NPC. Insensitivity to the exogenous 
cytokine hence cannot be explained by saturat-
ing levels of autocrine TGF-beta. As previously 
described, TGF-beta did not affect the clono-
gencity of NPCs which was found to be en- 
hanced when p53 was mutated (Figure 3A).
P53mut/mut NPC resisted TGF-beta-induced 
growth arrest even though the components of 
the TGF-beta signaling were intact
Cordenonsi et al. identified p53 as co-factor for 
TGF-beta signaling in Xenopus embryos and 
could show that p53 is required for TGF-beta 
induced growth arrest in Hep2G cells [28]. To 
investigate how p53 contributes to TGF-beta 
induced growth arrest in NPC, we investigated 
the expression of key proteins of TGF-beta 
signaling. There was no difference in the ex- 
pression of TGF-beta receptor 2 (Figure 3B). 
Likewise, SMAD2 expression was similar. 
SMAD7, which acts as a TGF-beta receptor 
antagonist and prevents the phosphorylation of 
SMAD2 was not amplified, either (Figure 3C). 
Rapid and equal phosphorylation of SMAD2 
in p53wt/wt, p53wt/mut, and p53mut/mut NPC con-
Figure 1. P53mut/mut NPC show enhanced proliferation compared to p53wt/wt NPC. A. Neurospheres formed from 
p53wt/wt and p53mut/mut NPCs were photographed after 5 days in culture. B. Based on the recorded images, the di-
ameter of neurospheres was assessed. Shown are median values and standard deviations for the size of spheres 
formed from p53wt/wt and p53mut/mut NPC (**P<0.01). C. Clonogenicity of untreated p53wt/wt NPC as compared to 
p53mut/mut NPC was determined (**P<0.01). D. The amplification rate (i.e. the number of viable cells divided by the 
number of cells plated) was determined for p53mut/mut and p53wt/wt NPCs (***P<0.001).
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firmed that SMAD2 activation by TGF-beta 
occurs independent of p53 function (Figure 
3D) and without increased SMAD2 expres- 
sion (Figure 3E). However, SMAD2 transloca-
tion into the nucleus was only observed in 
p53wt/wt NPC but not in p53mut/mut NPC (Figure 
4A) suggesting that the canonical TGF-beta sig-
naling cascade was impaired downstream of 
the receptor signaling complex. This is in line 
with previous reports describing that mutant 
p53 both attenuates and alters the TGF-beta-
induced transcription activity of SMAD2/3 pro-
teins [25, 28, 29]. A molecular explanation was 
offered by Cordenonsi et al. who found that the 
TGF-beta dependent interaction interaction of 
p53 with Smads 2 and 3 and the subsequent 
recruitment of SMAD4 to the nuclear transloca-
tion complex depends on the phosphorylation 
(and hence on the functionality) of p53. As 
a consequence, TGF-beta addition failed to 
induce p21 expression in p53mut/mut NPC where-
as p21 was readily induced in p53wt/wt NPC 
(Figure 5A). As this protein is a key effector for 
TGF-beta-mediated growth inhibition, the dif-
ferential induction of p21 explains why func-
tional p53 is a required co-factor for TGF-beta 
induced growth arrest.
Impaired autocrine TGF-beta signaling may 
contribute to the increased proliferation of 
p53mut/mut NPC
P53mut/mut mice show increased proliferation in 
the subventricular zone [14] which further pro-
Figure 2. P53mut/mut NPC does not respond to TGF-beta induced growth arrest. A. Shown are representative images 
depicting the change of growth pattern of p53wt/wt and p53mut/mut NPC in the absence or presence of TGF-beta (10 ng/
ml TGF-beta 1 and 2). B. Using the Alamar Blue assay, the proliferation of p53wt/wt and p53mut/mut NPC was assessed 
in the presence of 10 ng/ml TGF-beta 1/2 (**P<0.01, ***P<0.001). C. Shown are representative images of p53wt/
wt and p53mut/mut NPC in the absence or presence of 10 ng/ml TGF-beta 1/2 or 25 nM SB431542 (Scalebars: 500 
µM). D. Cell number relative to control conditions of p53wt/wt and p53mut/mut NPC treated with 10 ng/ml TGF-beta 1/2 
or 25 nM SB431542 or both (*P<0.05, **P<0.01).
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gresses into glioma-like tumors in mice [11]. 
We wondered whether impaired autocrine TGF-
beta signaling may contribute to the increased 
proliferation of NPC. To assess effects of auto-
crine TGF-beta signaling in NPC, NPC were 
treated with the specific TGF-beta receptor 
kinase inibitor SB431542, resulting in incre- 
ased proliferation of p53wt/wt NPC (Figure 2C, 
2D) but not in p53mut/mut NPC (Figure 5B-D). 
Autocrine TGF-beta signaling thus seems to be 
active in NPC. Anti-proliferative effects, howev-
er, appear to be restricted to p53wt/wt cells.
Discussion
NPC derived from neurogenic zones within the 
adult brain are likely cells of origin for GBM. 
Mice with conditional mutations in the brain 
develop hyperplasia within the SVZ and-later-
GBM-like tumors that develop from these cells 
in the SVZ [11]. This suggests that p53 muta-
tions result in premalignant lesions in the brain 
that later (likely upon acquisition of further 
genetic hits) progress to highly malignant 
tumors. In our experiments, we could confirm 
the increased proliferation rate of p53mut/mut 
cells in vitro. Loss of p53 function specifically 
prevented TGF-beta-induced growth arrest due 
to impaired translocation of SMAD2/4 into the 
nucleus. This resulted in the loss of TGF-beta 
mediated p21 induction, which likely contrib-
utes to increased proliferation of NPC in vitro 
and in vivo. The in vivo proof-of-concept of this 
hypothesis in a relevant tumor model would 
have been beyond the scope of this study. In 
addition, p53mut/mut NPC still proliferated slightly 
faster than p53wt/wt NPC even when the TGF-
beta receptor kinase inhibitor SB431542 was 
present. This suggests that p53 also limits the 
proliferation of NPC by TGF-beta independent 
signaling pathways not explored in this study.
TGF-beta makes an important contribution to 
the decrease of neurogenesis in the aging brain 
[18, 19]. Our data suggest that this effect may 
strongly depend on p53. This could also exlain 
why mutation or inactivation of p53 - which 
occurs early during gliomagenesis [9] - fosters 
Figure 3. In spite of being refractory the the growth-inhibitory effects of TGF-beta, p53mut/mut NPC do not lack any 
components of the canonical TGF-beta signaling pathway. A. p53wt/wt and p53mut/mut NPC were treated with 10 ng/ml 
TGF-beta 1/2 and clonogenicity was determined after 1-2 weeks. B. Expression of TGFBR2 was assessed by West-
ern Blotting, using beta-actin as loading control. C. SMAD2 and SMAD7 mRNA expression was assessed by PCR. D. 
Cells were treated with 10 ng/ml TGF-beta 1/2 and analyzed for SMAD2 phosphorylation, beta-actin and SMAD2 
expression at the indicated time points.
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the growth and migration of genetically altered 
NPC in the brain. It is therefore tempting to 
speculate that p53 dysfunction may predis-
pose NPC towards the formation of glial tumors. 
Possible effects of p53 inactivation on neuro-
genesis were not investigated in our study.
A classical step in the malignisation of epitheli-
al derived cancers like breast cancer is the con-
version of TGF-beta from tumor suppressor to 
tumor promoter. Together with published data 
[25] our findings offer a possible explanation 
for this shift. Inactivation of p53 is typically an 
early event in the genesis of gliomas, which 
directly protects the putative cells of origin 
against the anti-proliferative functions of TGF-
beta. Consequently, TGF-beta would loose its 
tumor suppressor function at an early stage 
during gliomagenesis. The premalignant tumors 
could therefore upregulate TGF-beta and there-
by induce local immunosuppression without 
having to acquire additional mutations in the 
TGF-beta pathway.
While these considerations inevitably contain a 
certain amount of speculation on early events 
during tumorigenesis, our work provides new 
insights into the potentially first steps during 
glioma development. Based on the data pre-
sented in this manuscript we propose that inac-
tivation of p53 in a single NPC does not only 
inhibit the guardian of the genome but also 
inactivate the TGF-beta dependent mechanism 
which would otherwise control neurogenesis in 
the ageing brain. The simultaneous disruption 
of these two important control mechanisms 
may therefore allow the formation of a prema-
lignant lesion, which can later develop into full-
blown glioma.
Figure 4. Intracellular translocation of SMAD2. Using epifluorescence microscopy, translocation of SMAD2 into the 
nucleus was monitored 30 min after addition of 10 ng/ml TGF-beta 1/2. DAPI was used as nuclear counterstain.
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